<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753671</url>
  </required_header>
  <id_info>
    <org_study_id>2020_14</org_study_id>
    <secondary_id>2020-A03000-39</secondary_id>
    <nct_id>NCT04753671</nct_id>
  </id_info>
  <brief_title>QUANTRA® References Range Protocol in Pregnancy and Postpartum</brief_title>
  <acronym>QUANTRA®_GPP</acronym>
  <official_title>Normal Pregnancy and Postpartum Reference Ranges Intervals for QUANTRA® (STAGO BIOCARE) Hemostasis Point of Care Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postpartum hemorrhage (PPH) remains the leading cause of maternal death. PPH associated&#xD;
      coagulopathy varies and their treatments (tranexamic acid, fibrinogen concentrates,plasma,&#xD;
      platelets need to be targeted and administrated early. Point of care hemostasis devices are&#xD;
      helpful to develop this strategy. Quantra® (STAGO BIOCARE) use an innovative method to detect&#xD;
      the clot formation. Pregnancy and non-hemorrhagic postpartum reference ranges are missing.&#xD;
      The objective of this study is to establish these norms needed to elaborate thereafter the&#xD;
      thresholds to be targeted in PPH conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the QUANTRA® parameters range intervals before and after vaginal delivery</measure>
    <time_frame>At admission (= before delivery )</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the QUANTRA® parameters range intervals before and after vaginal delivery</measure>
    <time_frame>At 30 minutes +/- 10 minutes after delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the QUANTRA® parameters range intervals before and after vaginal delivery</measure>
    <time_frame>At 30 up to 60 minutes after birth and placental removal.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between end of pregnancy and immediate postpartum reference values (both vaginal and caesarean deliveries)</measure>
    <time_frame>At 30 up to 60 minutes after birth</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pregnancy Postpartum</condition>
  <eligibility>
    <study_pop>
      <textblock>
        a cohort of Healthy pregnant woman (indemne of any chronic pathology neither obstetrical&#xD;
        pathology)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy pregnant woman (indemne of any chronic pathology neither obstetrical&#xD;
             pathology)&#xD;
&#xD;
          -  Delivering vaginally without postpartum hemorrhage for 60 patients&#xD;
&#xD;
          -  Delivering through a programmed C-section for 20 patients&#xD;
&#xD;
          -  Having given a non-opposition agreement to participate in the study.&#xD;
&#xD;
          -  Major patient with social insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any acute or chronic hemostasis pathology before pregnancy or during pregnancy&#xD;
             instrumental delivery or cesarean section Postpartum bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Sophie DUCLOY-BOUTHORS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Sophie DUCLOY-BOUTHORS, MD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>anne-sophie.bouthors@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hop Jeanne de Flandre Chu Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <phone>0320445962</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemostasis</keyword>
  <keyword>pregnancy</keyword>
  <keyword>postpartum</keyword>
  <keyword>point of care</keyword>
  <keyword>coagulopathy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

